APYX
Apyx Medical Inc
3.00$
+4.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 61.9% | 70.1% | 75.6% | 72.8% | 93.6% | 90.5% | 89.2% | 88.4% | 83.0% | 88.8% | 87.0% | 87.5% | |
| 23.1% | 37.5% | 41.2% | 32.1% | 17.2% | 69.5% | 56.6% | 44.9% | 19.7% | 55.1% | 49.0% | 47.5% | |
| 23.1% | 37.5% | 41.2% | 32.1% | 81.7% | 69.5% | 56.6% | 44.9% | 19.7% | 55.1% | 49.0% | 47.5% | |
| 8.0% | 9.3% | 13.5% | 15.7% | 5.3% | 10.9% | 23.4% | 30.8% | 35.2% | 17.7% | 23.9% | 25.1% | |
| 23.1% | 18.9% | 17.5% | 21.1% | 5.5% | 6.0% | 5.5% | 9.9% | 22.8% | 12.5% | 11.7% | 12.9% | |
| 28.0% | 21.7% | 18.4% | 20.7% | 6.1% | 7.8% | 9.7% | 9.6% | 13.1% | – | – | – | |
| – | 0.6% | 0.5% | 0.6% | 0.2% | – | – | – | – | – | – | – | |
| 7.8% | 5.8% | 4.9% | 5.5% | 0.0% | – | – | – | – | – | – | – | |
| 81.1% | 25.6% | 25.3% | 28.9% | 8.2% | 15.8% | 13.8% | 21.4% | 27.0% | 66.0% | 77.9% | 77.8% | |
| 15.2% | 13.1% | 15.0% | 19.3% | 8.1% | 14.5% | 12.4% | 19.2% | 22.9% | 16.1% | 16.5% | 17.5% | |
| 1.0% | 0.8% | 0.7% | 0.8% | – | 0.6% | 0.5% | 0.4% | 0.5% | 0.5% | 0.5% | 0.6% | |
| 6.3% | 3.9% | 4.6% | 5.1% | 1.5% | 2.9% | 2.0% | 3.8% | 5.2% | 3.4% | 4.0% | 4.6% | |
| 63.6% | 10.6% | 8.1% | 8.4% | 0.1% | – | – | – | – | 41.9% | 52.3% | 52.1% | |
| 18.9% | 74.4% | 74.7% | 71.1% | 91.8% | 84.2% | 86.0% | 78.1% | 72.6% | 33.7% | 21.9% | 21.8% | |
| -112.1% | -62.0% | -66.7% | -92.0% | 37.1% | 17.1% | 3.5% | -18.3% | -69.0% | -68.7% | -120.2% | -133.3% | |
| 71.5% | 88.2% | 78.2% | 101.4% | 35.9% | 40.2% | 46.2% | 50.0% | 66.7% | 43.7% | 54.8% | 63.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.